Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed
December 12th 2023OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Read More
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Read More
Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023
Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.
Read More
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Read More
Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.
Read More
Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
What is the Role of Bispecifics in Relapsed/Refractory DLBCL?
Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
Read More
Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy
A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
Read More
Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL
Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Read More
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel
A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel
Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
Read More
Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL
Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Read More
Factors in Selecting Treatment for Relapsed/Refractory DLBCL
Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Overview of Relapsed/Refractory DLBCL and Management Strategies
Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
Read More
Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma
Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
Read More